Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.


24 June 2021

ILC 2021: Symposium „Old and new treatments for patients with advanced cirrhosis”

Very successful symposium on Thursday, 24th June 2021 from 14-15h CEST organised by members of DECISION in the frame of the virtual ILC congress. Topics included:

Why and how to modulate the microbiome: example from MICROB-PREDICT study (Shawcross)

Old drugs for novel treatment strategies (Posé)

Human albumin: from established indications to novel perspectives (Caraceni)

System medicine: is it the right track to personalized treatments: example from DECISION study? (Trebicka)

More news


02 September 2021

DECISION Symposium connected to EASL School on Hepatology 2021

Symposium on ‘Management of acute-on-chronic liver failure’

Course director: Prof. Wim Laleman

Date: Thursday, 02 September 2021


Read full announcement

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more